Annual report pursuant to Section 13 and 15(d)

Note 14 - Collaborative Agreements (Details Textual)

v3.24.1
Note 14 - Collaborative Agreements (Details Textual) - USD ($)
$ in Millions
Nov. 04, 2021
Jun. 13, 2018
Mar. 21, 2016
CrystalGenomics, Inc. [Member]      
Collaborative Agreement, Milestone Payment     $ 16.0
Collaborative Agreement, Regulatory Milestone     $ 44.0
Tuspetinib Licensing Agreement [Member]      
License Fee, Total $ 12.5    
Payments for License Fee 5.0    
Stock Issued During Period, Value, Licensing Fee $ 7.5    
Stock Issued During Period, Shares, Licensing Fees (in shares) 215,703    
Clinical Development and Global Regulatory Milestone, First Indication $ 64.5    
Clinical Development and Global Regulatory Milestone, Second Indication 34.0    
Clinical Development and Global Regulatory Milestone, Third Indication 29.0    
Global Sales Milestone $ 280.0    
Exclusive License to CG806 in China, Development Milestones [Member] | CrystalGenomics, Inc. [Member]      
Collaborative Agreement, Regulatory Milestone   $ 6.0  
Exclusive License to CG806 in China, Regulatory Milestones [Member] | CrystalGenomics, Inc. [Member]      
Collaborative Agreement, Regulatory Milestone   $ 20.0